Genmab A/S's (GMAB) "Equal Weight" Rating Reaffirmed at Morgan Stanley

Genmab A/S (NASDAQ:GMAB - Get Free Report)'s stock had its "equal weight" rating reaffirmed by equities researchers at Morgan Stanley in a research report issued to clients and investors on Wednesday, Benzinga reports. They presently have a $31.00 target price on the stock. Morgan Stanley's target price would suggest a potential upside of 15.11% from the company's previous close.

A number of other brokerages have also weighed in on GMAB. JPMorgan Chase & Co. restated a "neutral" rating on shares of Genmab A/S in a research note on Tuesday, August 20th. HC Wainwright restated a "buy" rating and issued a $50.00 price objective on shares of Genmab A/S in a research report on Tuesday, August 27th. Royal Bank of Canada upgraded shares of Genmab A/S from a "sector perform" rating to an "outperform" rating in a research report on Monday, July 15th. Truist Financial cut their price target on shares of Genmab A/S from $53.00 to $50.00 and set a "buy" rating for the company in a research note on Monday. Finally, BTIG Research raised their price objective on shares of Genmab A/S from $46.00 to $47.00 and gave the company a "buy" rating in a research report on Thursday, June 27th. Two investment analysts have rated the stock with a sell rating, three have issued a hold rating and eight have issued a buy rating to the company's stock. According to MarketBeat.com, the company presently has an average rating of "Hold" and an average price target of $45.20.

Genmab A/S Trading Down 2.1 %

Shares of Genmab A/S stock traded down $0.57 on Wednesday, reaching $26.93. The stock had a trading volume of 338,331 shares, compared to its average volume of 574,078. The business's 50 day moving average is $27.16 and its two-hundred day moving average is $28.10. The company has a market cap of $17.81 billion, a P/E ratio of 22.34, a price-to-earnings-growth ratio of 0.87 and a beta of 0.99. Genmab A/S has a 1 year low of $24.53 and a 1 year high of $38.80.

Genmab A/S (NASDAQ:GMAB - Get Free Report) last posted its earnings results on Thursday, August 8th. The company reported $0.22 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.29 by ($0.07). Genmab A/S had a return on equity of 17.48% and a net margin of 29.06%. The firm had revenue of $779.50 million during the quarter, compared to analysts' expectations of $734.60 million. On average, equities analysts anticipate that Genmab A/S will post 1.21 EPS for the current fiscal year.

Institutional Investors Weigh In On Genmab A/S

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Sanctuary Advisors LLC purchased a new position in Genmab A/S during the 2nd quarter valued at about $1,354,000. Point72 Asset Management L.P. bought a new stake in shares of Genmab A/S in the 2nd quarter worth approximately $457,000. Cubist Systematic Strategies LLC grew its position in shares of Genmab A/S by 109.7% in the 2nd quarter. Cubist Systematic Strategies LLC now owns 278,541 shares of the company's stock worth $7,000,000 after buying an additional 145,689 shares during the last quarter. Benjamin F. Edwards & Company Inc. increased its stake in shares of Genmab A/S by 7.1% during the second quarter. Benjamin F. Edwards & Company Inc. now owns 7,227 shares of the company's stock valued at $182,000 after buying an additional 478 shares during the period. Finally, Renaissance Technologies LLC raised its holdings in shares of Genmab A/S by 7.6% during the second quarter. Renaissance Technologies LLC now owns 1,462,459 shares of the company's stock valued at $36,752,000 after acquiring an additional 103,859 shares in the last quarter. 7.07% of the stock is currently owned by institutional investors.

About Genmab A/S

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.